FDA Touts Biosimilar Approvals in Annual CDER Report

In 2019 the FDA approved 48 novel drugs and 10 biosimilars, according to the Center for Drug Evaluation and Research (CDER).
The Center for Biosimilars Staff
January 07, 2020
The FDA highlighted biosimilar approvals in its annual report of 2019 drug approvals released this week.

In 2019 the FDA approved 48 novel drugs and 10 biosimilars, according to the Center for Drug Evaluation and Research.

The biosimilar approvals “will further help to create competition, increase patient access, and potentially reduce the cost of important biological drug therapies,” the FDA said.

The 10 biosimilar approvals span indications for rheumatoid arthritis, plaque psoriasis, breast cancer, metastatic stomach cancer, metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.

The approvals include:
  • The fourth approved biosimilar infliximab, Amgen’s Avsola.
  • The second biosimilar etanercept, Samsung Bioepis’ Eticovo (referencing Enbrel).
  • Two adalimumab products, Hadlima and Abrilada, respectively the fourth and fifth biosimilars to Humira.
  • Three biosimilars for trastuzumab, Ontruzant, Trazimera, and Kanjinti; they are the third, fourth, and fifth biosimilars to reference trastuzumab, Herceptin.
  • Ruxience, the second biosimilar rituximab referencing the originator, Rituxan.
  • Ziextenzo, the third pegfilgrastim biosimilar to originator product Neulasta.
  • Pfizer’s biosimilar bevacizumab (Zirabev) the second biosimilar to Avastin. Zirabev launches in the United States January 13, 2020.
CDER has now approved a total of 26 biosimilars for 9 different reference products since 2015. In 2018 the FDA approved 59 novel drugs.
 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.